Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (EQ) is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing innovative therapies for autoimmune and inflammatory disorders with significant unmet medical needs. Founded in 2017, Equillium has quickly established itself as a frontrunner in the biopharmaceutical industry through its focus on novel treatments that modulate the immune system.
The company’s primary product candidate is itolizumab, a unique monoclonal antibody targeting the immune checkpoint receptor CD6. Itolizumab is currently in advanced clinical trials, specifically a Phase 1b/2 trial for the treatment of acute graft-versus-host disease (aGVHD) and a Phase 1 trial for asthma and lupus nephritis. This promising treatment has shown potential in modulating immune responses and reducing inflammation, providing hope for patients suffering from severe autoimmune conditions.
In addition to itolizumab, Equillium's pipeline includes other groundbreaking therapies. EQ101 is a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15. EQ101 is Phase 2-ready and is expected to begin patient enrollment for an alopecia areata study in the second half of 2022. Another noteworthy drug is EQ102, a cytokine inhibitor that targets IL-15 and IL-21, which is also ready for clinical development and will soon begin enrolling patients in a Phase 1 trial, including those with celiac disease.
Equillium’s commitment to addressing immuno-inflammatory disorders is further demonstrated through its strategic partnerships and collaborations. These alliances have enabled the company to enhance its research capabilities, expedite clinical trials, and bring novel treatments to market more efficiently.
Financially, Equillium is well-positioned to continue its research and development activities. The company has secured funding through various channels, ensuring the advancement of its clinical programs. By focusing on diseases with high unmet needs and leveraging its unique approach to immune modulation, Equillium aims to deliver impactful therapies that improve patient outcomes and quality of life.
For the latest updates on Equillium, Inc., including recent achievements and ongoing projects, keep an eye on their official communications and news releases.
Equillium, Inc. (Nasdaq: EQ) presented key research at ACR Convergence, indicating that urinary soluble ALCAM (sALCAM) may serve as a biomarker for disease severity in lupus nephritis (LN), potentially aiding in treatment response assessment. This study aligns urinary ALCAM levels with existing measures of LN, suggesting a less invasive alternative to kidney biopsies. Dr. Maple Fung highlighted its significance for patient monitoring. Itolizumab, Equillium's first-in-class monoclonal antibody, targets the CD6-ALCAM pathway and is currently undergoing clinical studies for its effectiveness in treating severe autoimmune disorders.
Equillium has launched a Phase 2 proof-of-concept study for EQ101 targeting alopecia areata, a common autoimmune condition. This open-label trial will involve approximately 30 adult subjects in Australia over 24 weeks, assessing efficacy, safety, tolerability, and pharmacokinetics. EQ101 inhibits key cytokines IL-2, IL-9, and IL-15, potentially offering a more selective treatment than current options. Previous studies indicated EQ101's safety and effectiveness in related conditions. The study's results are anticipated in 2023, marking a significant advancement in Equillium's pipeline.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced its participation in the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. Company management will present an overview of their clinical assets and discuss upcoming milestones. The Stifel conference is set for November 15 at Lotte New York Place Hotel, while the Jefferies conference will occur on November 17 in London. Webcast access will be available on their website, with archived replays for 90 days.
Equillium presented data on its novel Multi-Cytokine Inhibitor EQ101 for treating alopecia areata at the 6th Annual Dermatology Drug Development Summit. The presentation, made by Dr. Stephen Connelly, highlighted EQ101's selective targeting of IL-2, IL-9, and IL-15 with a favorable safety profile. A Phase 2 study is set to initiate in Q4 2022, aiming to evaluate its efficacy compared to other treatments. EQ101 demonstrated superior hair regrowth compared to ruxolitinib and has previously shown promise in cutaneous T cell lymphoma.
Equillium, Inc. (Nasdaq: EQ) announced the initiation of a Phase 1 study for its investigational drug EQ102, targeting celiac disease. The study involves up to 64 healthy volunteers and aims to evaluate safety and tolerability after administering single and multiple ascending doses. EQ102 is designed to inhibit cytokines IL-15 and IL-21, which are implicated in gastrointestinal inflammation. The CEO highlighted this as a significant milestone, with initial clinical data expected next year. Celiac disease has over 50 million global incidences and currently lacks effective treatments.
Equillium, Inc. (Nasdaq: EQ) presented promising data on its multi-cytokine inhibitors, EQ101 and EQ102, at the La Jolla Immunology Conference. The research indicates that these inhibitors effectively reduce the activity of cytotoxic T lymphocytes and natural killer cells, which are pivotal in autoimmune diseases.
EQ101 and EQ102 demonstrated approximately 50% and 40% reductions in CD4 and CD8 T cell proliferation, respectively. The company plans to initiate a Phase 2 study for EQ101 in alopecia areata and a Phase 1 study for EQ102 in healthy volunteers by year-end 2022.
Equillium announced interim results from the EQUALISE study evaluating itolizumab in lupus nephritis patients. Of the 6 subjects evaluated, 83% achieved a complete or partial response, and 67% attained over 80% reduction in urine protein creatinine ratio (UPCR) by week 28. The treatment showed a favorable safety profile with no serious adverse events. The mean baseline UPCR was notably high at 5.8 g/g, and the study's results point to potential as a competitive therapy in a field where other treatments have fallen short.
Equillium, Inc. (Nasdaq: EQ) announces the acceptance of its abstract for presentation at ACR Convergence, the American College of Rheumatology’s annual meeting, set for November 10-14, 2022. The abstract, titled 'Urine ALCAM is a Strong Predictor of Lupus Nephritis', highlights urinary soluble ALCAM as a potential biomarker for disease severity in lupus nephritis. Equillium develops novel therapeutics targeting autoimmune disorders, including itolizumab, currently undergoing clinical trials for conditions like lupus nephritis and acute graft-versus-host disease.
Equillium will acquire Metacrine in an all-stock merger, strengthening its financial position with an additional
Equillium, a clinical-stage biotechnology company, announces participation in the Wells Fargo Healthcare Conference on September 7 and the H.C. Wainwright Annual Global Investment Conference on September 12. The company will provide insights into its clinical assets and upcoming milestones.
The Wells Fargo event will take place at Encore Boston Harbor at 1:20 PM PT, while the H.C. Wainwright event will be held at Lotte New York Palace Hotel at 12:00 PM PT. Webcast access will be available on Equillium's website.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
What does Equillium, Inc. specialize in?
What is itolizumab?
What other products are in Equillium's pipeline?
Where is Equillium, Inc. headquartered?
When was Equillium, Inc. founded?
What are the current clinical trials for itolizumab?
What is the focus of EQ101?
What conditions is EQ102 targeting?
How is Equillium funded?
How can I stay updated on Equillium, Inc.'s latest news?
